OOIR: Observatory of International Research

Papers

(The median citation count of Annual Review of Pharmacology and Toxicology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Age-Related Perioperative Neurocognitive Disorders: Experimental Models and Druggable Targets	117
Measuring Pharmacogene Variant Function at Scale Using Multiplexed Assays	111
How Biologics Have Changed the Drug Discovery Landscape	103
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease	92
Pharmacology of Intestinal Inflammation and Repair	88
Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology	66
Evolving Approaches for Pharmacological Therapy of Obesity	66
Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities	63
Mitogen-Activated Protein Kinase Phosphatases: No Longer Undruggable?	62
Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development	61
Introduction to the Theme “Pharmacological Individuality: New Insights and Strategies for Personalized and Precise Drug Treatment”	60
E-Cigarette Toxicology	58
Introduction to the Theme “Development of New Drugs: Moving from the Bench to Bedside and Improved Patient Care”	56
	55
The Gut Microbiome, Metformin, and Aging	53
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer	52
Inhibitors of Intracellular RyR2 Calcium Release Channels as Therapeutic Agents in Arrhythmogenic Heart Diseases	51
Hear and Now: Ongoing Clinical Trials to Prevent Drug-Induced Hearing Loss	48
Endocannabinoid-Based Therapies	47
Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges	47
G Protein–Coupled Receptor Heteromers in Brain: Functional and Therapeutic Importance in Neuropsychiatric Disorders	46
OAT, OATP, and MRP Drug Transporters and the Remote Sensing and Signaling Theory	44
GPCR Biosensors to Study Conformational Dynamics and Signaling in Drug Discovery	44
Health Digital Twins in Life Science and Health Care Innovation	44
Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon	42

Synthetic Cannabinoids: A Pharmacological and Toxicological Overview	41
Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies	39
Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation	38
Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments	36
Pharmacogenetics of Antiplatelet Therapy	34
Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment	30
Prospects for Disease Slowing in Parkinson Disease	30
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy	30
Translational In Vivo Assays in Behavioral Biology	30
Oxidative Stress and Metabolism: A Mechanistic Insight for Glyphosate Toxicology	29
Drug Target Identification in Tissues by Thermal Proteome Profiling	28
G Protein–Coupled Estrogen Receptor GPER: Molecular Pharmacology and Therapeutic Applications	27
Targeting Efferocytosis in Inflammaging	26
What Structural Biology Tells Us About the Mode of Action and Detection of Toxicants	26
Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health	26
Progress and Challenges in the Field of Snakebite Envenoming Therapeutics	26
Resolution Pharmacology: Focus on Pro-Resolving Annexin A1 and Lipid Mediators for Therapeutic Innovation in Inflammation	26
Pharmacology of TRPC Channels and Its Potential in Cardiovascular and Metabolic Medicine	25
Pharmacological Induction of Granulocyte Cell Death as Therapeutic Strategy	25
Lysosomal Ion Channels: What Are They Good For and Are They Druggable Targets?	23
Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders	22
Alcohol Use Disorder Treatment: Problems and Solutions	21
Harnessing the Power of Electronic Health Records and Genomics for Drug Discovery	19
Brain-Protective Mechanisms of Transcription Factor NRF2: Toward a Common Strategy for Neurodegenerative Diseases	18
Treating Sickle Cell Disease: Gene Therapy Approaches	17
Advancements in Assays for Micro- and Nanoplastic Detection: Paving the Way for Biomonitoring and Exposomics Studies	17
Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response	16
Antiepileptic Drugs as Potential Dementia Prophylactics Following Traumatic Brain Injury	16
Deciphering Drug Targets and Actions with Single-Cell and Spatial Resolution	16
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation	15
Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure	15
G Protein–Coupled Receptor Signaling: New Insights Define Cellular Nanodomains	15
Precision Medicine Approaches for Infantile-Onset Developmental and Epileptic Encephalopathies	14
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics	13
Genetically Enriched Clinical Trials for Precision Development of Noncancer Therapeutics: A Scoping Review	13
Aryl Hydrocarbon Receptor and Its Diverse Ligands and Functions: An Exposome Receptor	13
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance	13
CaMKII as a Therapeutic Target in Cardiovascular Disease	13